Regulation of these devices is lax. Depending on the level
of risk, manufacturers can simply register them with the FDA prior to putting
them on the market or provide “reasonable assurance” of their safety and
efficacy. Clinical testing is the exception rather than the rule. Since 1976, the FDA had approved more than a thousand high-risk
devices, such as pacemakers. Of those, only sixteen percent had gone through
rigorous clinical testing before sale. Of the four hundred moderate-to
high-risk implants approved for market between 2008 and 2012, no clinical
testing was required. These devices included stents, replacement hips, surgical
mesh, and similar implants.
Of course, device makers make huge profits from their
products. In 2014, the industry’s estimated revenue was more than $136 billion.
To increase sales, they strive to constantly innovate. Thus, more untested
devices come onto the market.
Unlike Canada, Australia, Japan, New Zealand and several
European countries, the US has no registry of implants that would provide the
FDA, doctors, and patients with the risks and benefits of implants over time.
Repeated efforts to implement a registry system in the US have failed, thanks
to the implant industries’ powerful lobby.
As it is, people with implants are participants in a large
uncontrolled experiment.
For an introduction to this blog, see I Just Say No; for a list of blog topics, click the Topics tab.
For an introduction to this blog, see I Just Say No; for a list of blog topics, click the Topics tab.
No comments:
Post a Comment